NASDAQ:VTVT - vTv Therapeutics Stock Price, Forecast & News

vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT."

vTv Therapeutics Inc (NASDAQ:VTVT) issued its earnings results on Thursday, November, 8th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.12) by $0.06. The biotechnology company earned $3.38 million during the quarter, compared to the consensus estimate of $2.06 million. View vTv Therapeutics' Earnings History.

vTv Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for vTv Therapeutics.

2 analysts have issued twelve-month price targets for vTv Therapeutics' shares. Their forecasts range from $6.00 to $8.00. On average, they expect vTv Therapeutics' stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 152.7% from the stock's current price. View Analyst Price Targets for vTv Therapeutics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for vTv Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for vTv Therapeutics.

Press coverage about VTVT stock has trended negative on Thursday, according to InfoTrie. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. vTv Therapeutics earned a daily sentiment score of -2.1 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for vTv Therapeutics.

Some companies that are related to vTv Therapeutics include Arcus Biosciences (RCUS), AC Immune (ACIU), Assembly Biosciences (ASMB), Crinetics Pharmaceuticals (CRNX), Kura Oncology (KURA), Neoleukin Therapeutics (NLTX), Molecular Templates (MTEM), Catalyst Pharmaceuticals (CPRX), Ardelyx (ARDX), Axovant Sciences (AXON), Milestone Pharmaceuticals (MIST), Puma Biotechnology (PBYI), MacroGenics (MGNX), Clovis Oncology (CLVS) and Satsuma Pharmaceuticals (STSA).

Based on aggregate information from My MarketBeat watchlists, some companies that other vTv Therapeutics investors own include Agile Therapeutics (AGRX), VBI Vaccines (VBIV), Opko Health (OPK), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Micron Technology (MU), Canopy Growth (CGC), Crispr Therapeutics (CRSP) and Nabriva Therapeutics (NBRV).

(VTVT) raised $125 million in an initial public offering on Thursday, July 30th 2015. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Piper Jaffray and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.

vTv Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Bank of America Corp DE (0.24%), Barclays PLC (0.24%) and Renaissance Technologies LLC (0.07%). Company insiders that own vTv Therapeutics stock include Hersh Kozlov, Paul G Savas and Ronald O Perelman. View Institutional Ownership Trends for vTv Therapeutics.

VTVT stock was purchased by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Barclays PLC and Renaissance Technologies LLC. Company insiders that have bought vTv Therapeutics stock in the last two years include Hersh Kozlov, Paul G Savas and Ronald O Perelman. View Insider Buying and Selling for vTv Therapeutics.

Shares of VTVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of VTVT stock can currently be purchased for approximately $2.77.

vTv Therapeutics has a market capitalization of $149.94 million and generates $12.43 million in revenue each year. The biotechnology company earns $-7,910,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis. vTv Therapeutics employs 52 workers across the globe.View Additional Information About vTv Therapeutics.

The official website for vTv Therapeutics is http://www.vtvtherapeutics.com/.

vTv Therapeutics' mailing address is 4170 MENDENHALL OAKS PKWY, HIGH POINT NC, 27265. The biotechnology company can be reached via phone at 336-841-0300 or via email at [email protected]